Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder

NCT03282123 is registered in ClinicalTrials.gov with Resilient Pharmaceuticals as lead sponsor.

NCT NCT03282123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03282123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder
Lead sponsor
Resilient Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2017
Completion date
August 10, 2019
Enrollment
38 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd